Literature DB >> 21035522

Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus.

A Ludányi1, S S-J Hu, M Yamazaki, A Tanimura, D Piomelli, M Watanabe, M Kano, K Sakimura, Z Maglóczky, K Mackie, T F Freund, I Katona.   

Abstract

Clinical and experimental evidence demonstrates that endocannabinoids play either beneficial or adverse roles in many neurological and psychiatric disorders. Their medical significance may be best explained by the emerging concept that endocannabinoids are essential modulators of synaptic transmission throughout the central nervous system. However, the precise molecular architecture of the endocannabinoid signaling machinery in the human brain remains elusive. To address this issue, we investigated the synaptic distribution of metabolic enzymes for the most abundant endocannabinoid molecule, 2-arachidonoylglycerol (2-AG), in the postmortem human hippocampus. Immunostaining for diacylglycerol lipase-α (DGL-α), the main synthesizing enzyme of 2-AG, resulted in a laminar pattern corresponding to the termination zones of glutamatergic pathways. The highest density of DGL-α-immunostaining was observed in strata radiatum and oriens of the cornu ammonis and in the inner third of stratum moleculare of the dentate gyrus. At higher magnification, DGL-α-immunopositive puncta were distributed throughout the neuropil outlining the immunonegative main dendrites of pyramidal and granule cells. Electron microscopic analysis revealed that this pattern was due to the accumulation of DGL-α in dendritic spine heads. Similar DGL-α-immunostaining pattern was also found in hippocampi of wild-type, but not of DGL-α knockout mice. Using two independent antibodies developed against monoacylglycerol lipase (MGL), the predominant enzyme inactivating 2-AG, immunostaining also revealed a laminar and punctate staining pattern. However, as observed previously in rodent hippocampus, MGL was enriched in axon terminals instead of postsynaptic structures at the ultrastructural level. Taken together, these findings demonstrate the post- and presynaptic segregation of primary enzymes responsible for synthesis and elimination of 2-AG, respectively, in the human hippocampus. Thus, molecular architecture of the endocannabinoid signaling machinery supports retrograde regulation of synaptic activity, and its similar blueprint in rodents and humans further indicates that 2-AG's physiological role as a negative feed-back signal is an evolutionarily conserved feature of excitatory synapses. Copyright Â
© 2011 IBRO. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21035522      PMCID: PMC3678284          DOI: 10.1016/j.neuroscience.2010.10.062

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  76 in total

1.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

Review 2.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

3.  Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones.

Authors:  Alex Straiker; Ken Mackie
Journal:  J Physiol       Date:  2005-09-22       Impact factor: 5.182

4.  Immunohistochemical localization of candidates for vesicular glutamate transporters in the rat brain.

Authors:  Takeshi Kaneko; Fumino Fujiyama; Hiroyuki Hioki
Journal:  J Comp Neurol       Date:  2002-02-25       Impact factor: 3.215

5.  Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain.

Authors:  M Palkovits; J Harvey-White; J Liu; Z S Kovacs; M Bobest; G Lovas; A G Bagó; G Kunos
Journal:  Neuroscience       Date:  2008-02-05       Impact factor: 3.590

6.  Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy.

Authors:  Muthu D Bhaskaran; Bret N Smith
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

7.  Hippocampal distribution of vesicular glutamate transporter 1 in patients with temporal lobe epilepsy.

Authors:  W Saskia van der Hel; Suzanne A M W Verlinde; Dimphna H M Meijer; Marina de Wit; Marije G Rensen; Koen L I van Gassen; Peter C van Rijen; Cees W M van Veelen; Pierre N E de Graan
Journal:  Epilepsia       Date:  2009-04-06       Impact factor: 5.864

8.  Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.

Authors:  Carlos Solorzano; Chenggang Zhu; Natalia Battista; Giuseppe Astarita; Alessio Lodola; Silvia Rivara; Marco Mor; Roberto Russo; Mauro Maccarrone; Francesca Antonietti; Andrea Duranti; Andrea Tontini; Salvatore Cuzzocrea; Giorgio Tarzia; Daniele Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-19       Impact factor: 11.205

9.  The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum.

Authors:  Yoshinobu Kawamura; Masahiro Fukaya; Takashi Maejima; Takayuki Yoshida; Eriko Miura; Masahiko Watanabe; Takako Ohno-Shosaku; Masanobu Kano
Journal:  J Neurosci       Date:  2006-03-15       Impact factor: 6.167

10.  Predominant expression of phospholipase Cbeta1 in telencephalic principal neurons and cerebellar interneurons, and its close association with related signaling molecules in somatodendritic neuronal elements.

Authors:  Masahiro Fukaya; Motokazu Uchigashima; Sachi Nomura; Yuta Hasegawa; Hisaya Kikuchi; Masahiko Watanabe
Journal:  Eur J Neurosci       Date:  2008-11       Impact factor: 3.386

View more
  32 in total

Review 1.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

Review 2.  Monoacylglycerol lipase - a target for drug development?

Authors:  C J Fowler
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 3.  Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder.

Authors:  Mariah M Wu; Xinwen Zhang; Melissa J Asher; Stanley A Thayer
Journal:  Brain Res       Date:  2019-09-17       Impact factor: 3.252

Review 4.  Drug-Induced Alterations of Endocannabinoid-Mediated Plasticity in Brain Reward Regions.

Authors:  Natalie E Zlebnik; Joseph F Cheer
Journal:  J Neurosci       Date:  2016-10-05       Impact factor: 6.167

5.  Identification of mRNA for endocannabinoid biosynthetic enzymes within hippocampal pyramidal cells and CA1 stratum radiatum interneuron subtypes using quantitative real-time polymerase chain reaction.

Authors:  C B Merrill; M McNeil; R C Williamson; B R Poole; B Nelson; S Sudweeks; J G Edwards
Journal:  Neuroscience       Date:  2012-05-17       Impact factor: 3.590

Review 6.  Ghrelin Signaling: GOAT and GHS-R1a Take a LEAP in Complexity.

Authors:  Alfonso Abizaid; James L Hougland
Journal:  Trends Endocrinol Metab       Date:  2019-10-19       Impact factor: 12.015

Review 7.  An Introduction to the Endogenous Cannabinoid System.

Authors:  Hui-Chen Lu; Ken Mackie
Journal:  Biol Psychiatry       Date:  2015-10-30       Impact factor: 13.382

8.  A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects.

Authors:  Tiziana Bisogno; Anu Mahadevan; Roberto Coccurello; Jae Won Chang; Marco Allarà; Yugang Chen; Giacomo Giacovazzo; Aron Lichtman; Benjamin Cravatt; Anna Moles; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 9.  Endocannabinoid signaling and synaptic function.

Authors:  Pablo E Castillo; Thomas J Younts; Andrés E Chávez; Yuki Hashimotodani
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

Review 10.  The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.

Authors:  David W Volk; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-06-19       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.